Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

DISEASE CHARACTERISTICS:

• Histologically confirmed melanoma

  • Metastatic disease

• Measurable or evaluable non-CNS disease

  • Measurable disease, defined as a unidimensionally measurable lesion as determined by physical exam, x-ray, CT scan, MRI, or other radiographic procedure

  • Evaluable disease, defined as a lesion that can be seen radiographically but is not unidimensionally measurable

    • Previously irradiated lesions with documented progression are allowed provided there are no other sites of metastatic disease

• No active brain metastases

  • Previously treated, responding brain metastases allowed, provided there is measurable disease outside of the CNS

    • At least 3 weeks since prior chemotherapy and 6 weeks since prior radiotherapy for CNS disease

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status 0-2
• Life expectancy ≥ 3 months
• ANC ≥ 1,200/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
• Bilirubin ≤ 3.0 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• EKG with no evidence of serious arrhythmia or recent myocardial infarction

Exclusion criteria:

• Active infection
• Chronic underlying immunodeficiency disease
• Other serious concurrent illness
• Other forms of cancer within 5 years of initial diagnosis except nonmelanoma skin cancer and cervical cancer
• Congestive heart failure or myocardial infarction within the past 6 months

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• See Disease Characteristics
• At least 6 weeks since prior radiotherapy
• More than 4 weeks since prior surgery
• Prior biologic therapy allowed

Exclusion criteria:

• Prior cytotoxic agents
• Prior sorafenib tosylate, bevacizumab, or oxaliplatin
• Concurrent biological therapy, except growth factors for anemia, neutropenia, or thrombocytopenia
• Concurrent radiotherapy, chemotherapy, or surgery